Corey Michael Watton Sells 12,300 Shares of Zevra Therapeutics (NASDAQ:ZVRA) Stock

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Director Corey Michael Watton sold 12,300 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $11.25, for a total value of $138,375.00. Following the completion of the sale, the director directly owned 1,800 shares of the company’s stock, valued at $20,250. This trade represents a 87.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Zevra Therapeutics Price Performance

ZVRA opened at $11.18 on Friday. The firm has a market capitalization of $663.87 million, a PE ratio of 12.15 and a beta of 0.91. Zevra Therapeutics, Inc. has a fifty-two week low of $7.16 and a fifty-two week high of $15.03. The company’s 50-day moving average is $12.34 and its 200 day moving average is $10.65.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.14. The firm had revenue of $39.66 million during the quarter, compared to analyst estimates of $33.88 million. Zevra Therapeutics had a return on equity of 54.54% and a net margin of 42.82%. As a group, analysts expect that Zevra Therapeutics, Inc. will post 0.6 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on ZVRA shares. Maxim Group increased their price target on Zevra Therapeutics from $25.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, June 10th. Canaccord Genuity Group lowered their target price on shares of Zevra Therapeutics from $29.00 to $20.00 and set a “buy” rating for the company in a report on Monday, July 27th. Citizens Jmp raised their price target on shares of Zevra Therapeutics from $25.00 to $28.00 and gave the company a “market outperform” rating in a research report on Thursday, August 6th. UBS Group reaffirmed a “buy” rating on shares of Zevra Therapeutics in a research report on Wednesday, June 24th. Finally, Weiss Ratings lowered shares of Zevra Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research note on Friday, May 22nd. Nine research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.14.

Institutional Investors Weigh In On Zevra Therapeutics

A number of hedge funds have recently made changes to their positions in ZVRA. Adage Capital Partners GP L.L.C. grew its position in Zevra Therapeutics by 15.2% during the second quarter. Adage Capital Partners GP L.L.C. now owns 4,168,000 shares of the company’s stock valued at $36,720,000 after buying an additional 550,000 shares during the period. Vanguard Group Inc. boosted its stake in Zevra Therapeutics by 4.4% in the third quarter. Vanguard Group Inc. now owns 3,083,362 shares of the company’s stock valued at $29,323,000 after acquiring an additional 130,676 shares during the last quarter. Nantahala Capital Management LLC boosted its stake in Zevra Therapeutics by 34.0% in the third quarter. Nantahala Capital Management LLC now owns 1,971,936 shares of the company’s stock valued at $18,753,000 after acquiring an additional 500,000 shares during the last quarter. Rubric Capital Management LP boosted its stake in Zevra Therapeutics by 60.8% in the second quarter. Rubric Capital Management LP now owns 1,958,318 shares of the company’s stock valued at $17,253,000 after acquiring an additional 740,584 shares during the last quarter. Finally, State Street Corp grew its position in shares of Zevra Therapeutics by 3.9% during the 4th quarter. State Street Corp now owns 1,482,956 shares of the company’s stock valued at $13,287,000 after acquiring an additional 55,665 shares during the period. 35.03% of the stock is currently owned by institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.